First Symposium of the European Working Group on the Radiobiology of Molecular Radiotherapy

Bart Cornelissen; Samantha Terry; Julie Nonnekens; Jean-Pierre Pouget

First Symposium of the European Working Group on the Radiobiology of Molecular Radiotherapy

Bart Cornelissen, Samantha Terry, Julie Nonnekens, Jean-Pierre Pouget

Imaging Chemistry & Biology

Research output: Contribution to journal › Editorial

4 Citations (Scopus)

43 Downloads (Pure)

Abstract

Cancer therapy using radionuclides is gaining much attention. Attached to tumor-specific vectors, isotopes emitting α, β, or Auger electron particles are being increasingly investigated for their ability to deliver radiation damage selectively to cancer tissues. In light of the recent approval of 177Lu-DOTATATE and 223RaCl2 therapy by regulators on both sides of the Atlantic and the highly promising results just reported for 177Lu–prostate-specific membrane antigen, investment and research interests in these and other radionuclide therapies are rapidly expanding. The purpose of the European Working Group is to promote knowledge, investment, and networking in the area of (radio)biology of radionuclide therapy.

This report details recent research and inspiring insights presented at the inaugural International Workshop on Radiobiology of Molecular Radiotherapy, held as a hybrid meeting in Montpellier, France, on March 17 and 18, 2021.

Original language	English
Pages (from-to)	14N-15N
Journal	Journal of Nuclear Medicine
Volume	62
Issue number	7
Publication status	Published - Jul 2021

Access to Document

MRT symposium edit for review_JNM Newsline_BCAccepted author manuscript, 32.9 KBLicence: CC BY

https://jnm.snmjournals.org/content/62/7/14N

Cite this

@article{0c81d6d93b7a47d6a9b6253ee34ad3df,

title = "First Symposium of the European Working Group on the Radiobiology of Molecular Radiotherapy",

abstract = "Cancer therapy using radionuclides is gaining much attention. Attached to tumor-specific vectors, isotopes emitting α, β, or Auger electron particles are being increasingly investigated for their ability to deliver radiation damage selectively to cancer tissues. In light of the recent approval of 177Lu-DOTATATE and 223RaCl2 therapy by regulators on both sides of the Atlantic and the highly promising results just reported for 177Lu–prostate-specific membrane antigen, investment and research interests in these and other radionuclide therapies are rapidly expanding. The purpose of the European Working Group is to promote knowledge, investment, and networking in the area of (radio)biology of radionuclide therapy. This report details recent research and inspiring insights presented at the inaugural International Workshop on Radiobiology of Molecular Radiotherapy, held as a hybrid meeting in Montpellier, France, on March 17 and 18, 2021. ",

author = "Bart Cornelissen and Samantha Terry and Julie Nonnekens and Jean-Pierre Pouget",

year = "2021",

month = jul,

language = "English",

volume = "62",

pages = "14N--15N",

journal = "Journal of Nuclear Medicine",

issn = "1535-5667",

publisher = "Society of Nuclear Medicine and Molecular Imaging",

number = "7",

}

TY - JOUR

T1 - First Symposium of the European Working Group on the Radiobiology of Molecular Radiotherapy

AU - Cornelissen, Bart

AU - Terry, Samantha

AU - Nonnekens, Julie

AU - Pouget, Jean-Pierre

PY - 2021/7

Y1 - 2021/7

N2 - Cancer therapy using radionuclides is gaining much attention. Attached to tumor-specific vectors, isotopes emitting α, β, or Auger electron particles are being increasingly investigated for their ability to deliver radiation damage selectively to cancer tissues. In light of the recent approval of 177Lu-DOTATATE and 223RaCl2 therapy by regulators on both sides of the Atlantic and the highly promising results just reported for 177Lu–prostate-specific membrane antigen, investment and research interests in these and other radionuclide therapies are rapidly expanding. The purpose of the European Working Group is to promote knowledge, investment, and networking in the area of (radio)biology of radionuclide therapy. This report details recent research and inspiring insights presented at the inaugural International Workshop on Radiobiology of Molecular Radiotherapy, held as a hybrid meeting in Montpellier, France, on March 17 and 18, 2021.

AB - Cancer therapy using radionuclides is gaining much attention. Attached to tumor-specific vectors, isotopes emitting α, β, or Auger electron particles are being increasingly investigated for their ability to deliver radiation damage selectively to cancer tissues. In light of the recent approval of 177Lu-DOTATATE and 223RaCl2 therapy by regulators on both sides of the Atlantic and the highly promising results just reported for 177Lu–prostate-specific membrane antigen, investment and research interests in these and other radionuclide therapies are rapidly expanding. The purpose of the European Working Group is to promote knowledge, investment, and networking in the area of (radio)biology of radionuclide therapy. This report details recent research and inspiring insights presented at the inaugural International Workshop on Radiobiology of Molecular Radiotherapy, held as a hybrid meeting in Montpellier, France, on March 17 and 18, 2021.

M3 - Editorial

SN - 1535-5667

VL - 62

SP - 14N-15N

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 7

ER -

First Symposium of the European Working Group on the Radiobiology of Molecular Radiotherapy

Abstract

Access to Document

Fingerprint

Cite this